FDA turns back new drug for mixed dyslipidemia

Tuesday 30 March 2010

The US Food and Drug Administration has said it can’t approve a new lipid-lowering drug from AstraZeneca Plc and Abbott Laboratories without further data. The two companies announced receiving the complete response letter on 30 March 2010.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States